How many clinical trials are studying Tamoxifen 20 mg?

3 recruiting trials in our tracked data involve Tamoxifen 20 mg.

What conditions is Tamoxifen 20 mg being studied for?

In our tracked recruiting trials, Tamoxifen 20 mg is being studied in trials for Breast Cancer, Breast Neoplasms, HER2-negative Breast Cancer.

Tamoxifen 20 mg: clinical trials recruiting now

Q: Is Tamoxifen 20 mg FDA-approved?

Yes. According to the FDA drug label available through openFDA, Tamoxifen 20 mg is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Tamoxifen 20 mg appears in the FDA drug-label database. Marketed as SOLTAMOX.
Boxed warning: The FDA label for Tamoxifen 20 mg carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 ) For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer ( 1.2 ) To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS) ( 1.3 ) To reduce the incidence of breast cancer in adult women at high risk ( 1.4 ) 1.1 Metastatic Breast Cancer SOLTAMOX is indicated for the treatment of adult patients with estrogen receptor-positive metastatic breast cancer. 1.2 Adjuvant Treatment of Breast Cancer SOLTAMOX is indicated: for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer to reduce the occurrence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer. 1.3 Ductal Carcinoma in Situ In adult women with DCIS, following breast surgery and radiation, SOLTAMOX is indicated to reduce the risk of invasive breast cancer [see Boxed Warning and Clinical Studies (14.3) ] . 1.4 Reduction in Breast Cancer Incidence in Women at High Ri…

FDA label via openFDA

Phase breakdown

Phase 2 3

Conditions being studied

Condition	Trials
Breast Cancer	2
Breast Neoplasms	1
HER2-negative Breast Cancer	1
Hormone Receptor Positive Tumor	1
Pancreatic Neoplasms	1
Pancreatic cancer	1
Premenopausal Breast Cancer	1

Recruiting trials involving Tamoxifen 20 mg

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 89 locations
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
NCT05982093 · Phase: Phase 2 · Ages: 35 Years and older · Sex: Female · 15 locations
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
NCT06914674 · Phase: Phase 2 · Ages: 14 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

Is Tamoxifen 20 mg FDA-approved?

Yes, marketed as SOLTAMOX. Its FDA label carries a boxed warning.

How many recruiting trials involve Tamoxifen 20 mg?

3 recruiting trials across 7 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.